Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases
Objective. Neuroendocrine neoplasias (NENs) represent a rare and biologically heterogeneous group of malignancies. Treatment of NEN patients remains challenging due to lack of prospective evidence on the choice of ideal therapeutic sequence and therapeutic efficacy in specific individual scenarios....
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2020/1491475 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560128875823104 |
|---|---|
| author | Karin Mayer Selina Kiry Anna Yordanova Hojjat Ahmadzadehfar Florian C. Gaertner Ralph A. Bundschuh Markus Essler Maria A. Gonzalez-Carmona Christian P. Strassburg Hanno Matthaei Philipp Lingohr Savita Bisht Peter Brossart Georg Feldmann |
| author_facet | Karin Mayer Selina Kiry Anna Yordanova Hojjat Ahmadzadehfar Florian C. Gaertner Ralph A. Bundschuh Markus Essler Maria A. Gonzalez-Carmona Christian P. Strassburg Hanno Matthaei Philipp Lingohr Savita Bisht Peter Brossart Georg Feldmann |
| author_sort | Karin Mayer |
| collection | DOAJ |
| description | Objective. Neuroendocrine neoplasias (NENs) represent a rare and biologically heterogeneous group of malignancies. Treatment of NEN patients remains challenging due to lack of prospective evidence on the choice of ideal therapeutic sequence and therapeutic efficacy in specific individual scenarios. Methods. Clinical data on 110 consecutive patients suffering from NEN treated at a single German university center were analyzed, therapeutic regimens applied were assessed, and the outcome was evaluated. Results. Histological grading, Ki67 proliferation index, functional activity, and presence of metastases were identified as prognostic markers. 10-year overall survival rates were 92%, 44%, and 0% for G1, G2, and G3 tumors, and 60%, 39%, 69%, 53%, and 0% for Ki67 <2%, 3–5%, 6–20%, 21–49%, and >50%, respectively. Peptide receptor radionuclide therapy (PRRT) and cytostatic chemotherapy were the second most common options, with PRRT being used more frequently in NET G1 and G2 and chemotherapy in NEC G3. Combination chemotherapy with etoposide plus cisplatin or carboplatin showed disease control rates (DCRs) of overall 74%, with a short median progression-free survival (PFS) of 7 or 5 months, respectively. DCR and PFS for PRRT were 89% and 22 months when administered as monotherapy, versus 100% and 27 months upon combination with somatostatin analog (SSA) therapy. Of note, PRRT also achieved disease control as best response in 5/5 (100%) selected cases of NEC G3. Conclusion. Further prospective studies are warranted to help stratify available options for therapeutic intervention in NEN patients. |
| format | Article |
| id | doaj-art-9fb0366f3dec4d34bc01f67de49d4b03 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-9fb0366f3dec4d34bc01f67de49d4b032025-02-03T01:28:21ZengWileyInternational Journal of Endocrinology1687-83371687-83452020-01-01202010.1155/2020/14914751491475Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive CasesKarin Mayer0Selina Kiry1Anna Yordanova2Hojjat Ahmadzadehfar3Florian C. Gaertner4Ralph A. Bundschuh5Markus Essler6Maria A. Gonzalez-Carmona7Christian P. Strassburg8Hanno Matthaei9Philipp Lingohr10Savita Bisht11Peter Brossart12Georg Feldmann13Department of Internal Medicine 3, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Internal Medicine 3, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Nuclear Medicine, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Nuclear Medicine, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Nuclear Medicine, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Nuclear Medicine, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Nuclear Medicine, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Internal Medicine 1, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Internal Medicine 1, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Surgery, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Surgery, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Internal Medicine 3, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Internal Medicine 3, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyDepartment of Internal Medicine 3, Center of Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital of Bonn, Bonn, GermanyObjective. Neuroendocrine neoplasias (NENs) represent a rare and biologically heterogeneous group of malignancies. Treatment of NEN patients remains challenging due to lack of prospective evidence on the choice of ideal therapeutic sequence and therapeutic efficacy in specific individual scenarios. Methods. Clinical data on 110 consecutive patients suffering from NEN treated at a single German university center were analyzed, therapeutic regimens applied were assessed, and the outcome was evaluated. Results. Histological grading, Ki67 proliferation index, functional activity, and presence of metastases were identified as prognostic markers. 10-year overall survival rates were 92%, 44%, and 0% for G1, G2, and G3 tumors, and 60%, 39%, 69%, 53%, and 0% for Ki67 <2%, 3–5%, 6–20%, 21–49%, and >50%, respectively. Peptide receptor radionuclide therapy (PRRT) and cytostatic chemotherapy were the second most common options, with PRRT being used more frequently in NET G1 and G2 and chemotherapy in NEC G3. Combination chemotherapy with etoposide plus cisplatin or carboplatin showed disease control rates (DCRs) of overall 74%, with a short median progression-free survival (PFS) of 7 or 5 months, respectively. DCR and PFS for PRRT were 89% and 22 months when administered as monotherapy, versus 100% and 27 months upon combination with somatostatin analog (SSA) therapy. Of note, PRRT also achieved disease control as best response in 5/5 (100%) selected cases of NEC G3. Conclusion. Further prospective studies are warranted to help stratify available options for therapeutic intervention in NEN patients.http://dx.doi.org/10.1155/2020/1491475 |
| spellingShingle | Karin Mayer Selina Kiry Anna Yordanova Hojjat Ahmadzadehfar Florian C. Gaertner Ralph A. Bundschuh Markus Essler Maria A. Gonzalez-Carmona Christian P. Strassburg Hanno Matthaei Philipp Lingohr Savita Bisht Peter Brossart Georg Feldmann Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases International Journal of Endocrinology |
| title | Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases |
| title_full | Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases |
| title_fullStr | Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases |
| title_full_unstemmed | Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases |
| title_short | Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases |
| title_sort | systemic therapy of neuroendocrine neoplasia single center experience from a cohort of 110 consecutive cases |
| url | http://dx.doi.org/10.1155/2020/1491475 |
| work_keys_str_mv | AT karinmayer systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT selinakiry systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT annayordanova systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT hojjatahmadzadehfar systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT floriancgaertner systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT ralphabundschuh systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT markusessler systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT mariaagonzalezcarmona systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT christianpstrassburg systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT hannomatthaei systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT philipplingohr systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT savitabisht systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT peterbrossart systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases AT georgfeldmann systemictherapyofneuroendocrineneoplasiasinglecenterexperiencefromacohortof110consecutivecases |